Amaros, a developer of an ophthalmic AI platform, has closed on a series A financing round.
The additional funding will help the company continue product development, expand commercial partnerships and scale its engineering, clinical and data sciences teams, according to a June 17 news release.
The company’s EvidenceEngine platform integrates data sets including electronic medical records, imaging, genomics, provide notes and claims into real-time insights for the ophthalmology industry.
Amaros also formed an advisory board made up of seven eye care physicians and ophthalmologists to guide the platform’s commercialization and application.
The funding was backed by new and existing investors, the release said.
